CAJ | 학술논문

目的：探讨丝裂霉素膀胱内热灌注联合经尿道电切术对膀胱癌患者的疗效。方法选取浅表性膀胱癌患者64例，随机分为对照组和观察组，各32例。两组患者在行经尿道电切术1周后均行膀胱灌注化疗，其中对照组采用常温丝裂霉素灌注，观察组采用丝裂霉素热灌注治疗。结果3年随访结束后，观察组患者复发率较对照组显著降低（ P＜0.05），且观察组患者存活率较对照组显著延长（ P ＜0.05）。治疗后两组患者CD4＋/CD3＋较前均有明显升高，而对照组患者CD8＋/CD3＋较观察组升高明显（ P＜0.05）。治疗后观察组CD4＋/CD8＋较对照组明显升高（ P＜0.05）。两组患者不良反应发生率间未见明显统计学差异（ P＞0.05）。结论丝裂霉素膀胱内热灌注联合经尿道电切术，能显著降低疾病复发率并提高患者生存率，同时治疗过程安全，值得临床推广。
목적：탐토사렬매소방광내열관주연합경뇨도전절술대방광암환자적료효。방법선취천표성방광암환자64례，수궤분위대조조화관찰조，각32례。량조환자재행경뇨도전절술1주후균행방광관주화료，기중대조조채용상온사렬매소관주，관찰조채용사렬매소열관주치료。결과3년수방결속후，관찰조환자복발솔교대조조현저강저（ P＜0.05），차관찰조환자존활솔교대조조현저연장（ P ＜0.05）。치료후량조환자CD4＋/CD3＋교전균유명현승고，이대조조환자CD8＋/CD3＋교관찰조승고명현（ P＜0.05）。치료후관찰조CD4＋/CD8＋교대조조명현승고（ P＜0.05）。량조환자불량반응발생솔간미견명현통계학차이（ P＞0.05）。결론사렬매소방광내열관주연합경뇨도전절술，능현저강저질병복발솔병제고환자생존솔，동시치료과정안전，치득림상추엄。
Objective To investigate the efficacy of intravesical mitomycin hyPerthemal Perfusion combined with transurethral resection in treating bladder cancer. Methods 64 Patients with suPerficial bladder cancer were selected and randomly divided into the control grouP and the observation grouP, 32 cases in each grouP. Two grouPs of Patients were given intravesical mitomycin Perfusion 1 week after the transurethral resection. The control grouP was treated with mitomycin Perfusion at the room temPerature, and the observation grouP were treated with mitomycin hyPerthemal Perfusion. Results After 3 years of follow-uP, the recurrence rate of the observation grouP was significantly lower than that of the control grouP ( P < 0. 05 ) , and the survival rate of the observation grouP was significantly higher than that of the control grouP ( P < 0. 05 ) . The CD4 + /CD3+ of the two grouPs were significantly higher than before treatment, while the control grouP was significantly higher than that in the observation grouP ( P < 0. 05 ) . After treatment, the CD4 + /CD8 + of the obser-vation grouP was significantly higher than that of the control grouP ( P < 0. 05 ) . The incidence of adverse reactions in the two grouPs had no statistically significant difference ( P > 0. 05 ) . Conclusion Mitomycin hyPerthemal Perfusion combined with transurethral resection can significantly reduce the recurrence rate and imProve survival rate. At the same time, the treatment Process is safe, and is worth of clinical Promotion.